A Study of RAY1225 in Participants With Impaired Kidney Function

Phase 1

Completed

• Conditions: Kidney Impairment
• Interventions: Drug: RAY1225

• Registration Number: NCT06613763
• Lead Sponsor: Guangdong Raynovent Biotech Co., Ltd

Brief Summary

The purpose of this study is to assess how fast RAY1225 gets into the blood stream and how long it takes the body to remove it in participants with impaired kidney function compared to healthy participants.

Detailed Description

Not available

Study Timeline

• Status Verified: 2024-09
• Study Start: 2024-09-11
• Study First Submitted: 2024-09-23
• Study First Submitted QC: 2024-09-23
• Study First Posted: 2024-09-26
• Primary Completion: 2025-01-10
• Study Completion: 2025-01-20
• Last Update Submitted: 2025-03-04
• Last Update Posted: 2025-03-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 32

Inclusion Criteria

1. Body mass index (BMI) ≥18 to ≤28kg/m2 and total body weight >50 kg(male) or >40kg(female) at Screening (calculated as a function of measured height and weight according to the formula, BMI = kg / m2 where m2 is height in meters squared);

2. Ability to understand and willingness to sign a written informed consent form;

   Participants with normal renal function only:

3. Normal physical examination, vital signs, 12-lead ECG, Chest X-ray images (anteroposterior) and clinical laboratory values, or any abnormality that is non-clinically significant；

4. Glomerular filtration rate (GFR)≥ 90 mL/min and <130 mL/min ；

5. Age, BMI, and sex comparable to those of subjects of renal impairment；

   Participants with severe renal impairment only:

6. Diagnosis of CKD (any indicators of renal impairment or GFR < 60 mL/min/1.73 m2 for more than 3 months)；

Exclusion Criteria

1. Participants with an allergic disposition (multiple drug and food allergies) or who, have known allergies to RAY1225 or related compounds;

2. Have a personal or family history of medullary thyroid carcinoma or have multiple endocrine neoplasia syndrome type 2;

3. Participants who donated blood or bleeding profusely (> 400 mL) in the 3 months or donated blood or bleeding profusely (> 200 mL) in the 1 months;

4. Pregnant or lactating women, or women of childbearing age with a positive pregnancy test

5. Participants with serious infections, trauma, gastrointestinal surgery or other major surgical procedures within 4 weeks

   Participants with severe renal impairment only:

6. Participants with acute renal failure, or a kidney transplant history; or requiring renal dialysis during the study period;

7. Hypertension that is not well controlled with antihypertensive medication (systolic blood pressure ≥ 160mm Hg or diastolic blood pressure ≥ 100mm Hg)

8. New York heart association (NYHA) class III or IV congestive heart failure

9. Alanine aminotransferase (ALT) ≥ 2×ULN, aspartate aminotransferase(AST) ≥ 2×ULN; Serum total bilirubin > 1.5×ULN;

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
RAY1225 - Mild Renal Impairment	RAY1225	RAY1225 3mg administered SC to participants with mild renal impairment.
RAY1225 - Moderate Renal Impairment	RAY1225	RAY1225 3mg administered SC to participants with moderate renal impairment.
RAY1225 - Severe Renal Impairment	RAY1225	RAY1225 3mg administered SC to participants with severe renal impairment.
RAY1225 - Control	RAY1225	RAY1225 3 milligrams (mg) administered subcutaneously (SC) to healthy participants with normal renal function.

Primary Outcome Measures

Name	Time	Method
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of RAY1225 From Time Zero to T (AUC[0-t])	Baseline through Day 43
PK: Maximum Concentration of RAY1225	Baseline through Day 43

Secondary Outcome Measures

Name	Time	Method
Number and severity of participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events(SAE)	Baseline through Day 43

Trial Locations

Locations (1)

The First Affiliated Hospital of Xiamen University; 🇨🇳 Xiamen, Fujian, China